The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Well said Knowlesi... good balance!
C7,
I think it is far too early to be able to ascribe any sort of value to Covidity. It is easier with say SCIB1 since the cases of Melanoma are known, there have been no effective treatments for late stage melanoma developed over decades, we have both preclinical and human trial data to give us a level of confidence that it can progress to phase three trials and market.
Covid is different, it is relatively new and we have no data on its effectiveness yet. Also, the details of how the commercial model will work are very sketchy.
RayP, I don’t understand how you can “agree a list of questions”....who are you asking?..I am an independent private investor and I will ask the questions I feel I need to after reviewing the presentation material (when we see it!)... whether they get selected for a response is another question!...rest assured, I will not be looking for “agreement” from anyone... least of all the “Cosy Club” that exist on this BB.
ciaskin, yes three times the SP a 200% rise. Yeah I will take it too!!
Just for the sake of accuracy, 5.5p to 16.5p is a rise of 200%. I'll take it though!
Hi Ruck,
Yes, admittedly it was ""ludicrously cheap"", lol
Would tend to agree with you, but I didn"t see 19p coming, nor the 25p that the charts predicted at that time.
Data yes, so important, as I said Redmile must have felt data will emerge sooner rather than later, and with the covid situation rife again it just makes me wonder what they know that we don"t? And that is on a few items now.
From your reckonings how much value can we attach to Covidity now, again data playing a big part in that.??
Evening C7,
Yes I am reading!
I think there is a big difference rising 300% from undervalued to fair value to rising another 300%. For this to happen I think there needs to be positive news of trial progress.
Redmile have invested £40M not £45m, a substantial sum nonetheless.
ATB.
I actually don't have any questions for the AGM. I'd prefer them to tell me things I don't know.
"Whilst the Company may not be in a position to answer every question it receives, it will address the most prominent within the confines of information already disclosed to the market through regulatory announcements."
An update on the data please.
At this stage shouldn't we just write down the subject areas.
Something like:
SCIB1
SCIB2
MODI1
MODI2
Covidity
Avidimab
FG2811
The rest of the glycans mabs
New hires
Future plans outside the above
Then once the presentation is released, we can have a debate on what information is missing from the presentation.
I suggest we decide on a not too long a list, just pick out the more important ones.
Anything unanswered we could always ask CH by email later.
What do people think about this approach and am I being optimistic in thinking we could agree a list of questions :-)
Bunsie, well it is a good suggestion and my two choices would be Burble and Bermudashorts.
With the best will in the world many of us woule have good questions to ask,, bt I am sure quite a few them would not have a good chance of being answered unless very carefully worded, I have found that works well with the BOD although I haven"t e-mailed them for some time. There just seems to be so many questions to ask these days with more platforms and candidates
So many issues could well be answered by the BOD now we have the necessary funding to act, and the simple fact that Redmile have invested so heavily here suggests there are many reasons why and to which they are privy too.
With retrospect now Vulpes certainly had a Plan B, which was IMHO to keep the lights on and give them time to get an investor/s the size of Redmile on board. Perhaps too with the help of Big Pharma we have arrived at this situation, which has seen a great return for Vulpes, with no sign they will be selling out and now Redmile looking for an even bigger return, and that in itself shows us we at least come into that catagory by Redmiles external validation of Scancell alone.
I am certainly very excited by the opportunity afforded to us which again would have put Scancell under the microscope as was the case with Vulpes, and a small rise now to 16.5p would mean we have risen 300% from the days of 5.5p and funnily enough, Ruck are you reading?? another 300% puts us on 49.5p just .5p away from our 50p valuation. One of the most asked questions would probably be when can we envisage getting our trials recruiting and till first patients injected, which must have been very much on Redmiles minds, Just perhaps given the Covid situation ,that will be earlier than what some of us might have imagined.
It has been suggested by some that £45m is not a big investment from Redmile, well I don"t subscribe to that and as I felt with Vulpes, Redmile have a Plan B and C too, which IMHO will be collecting data from trials ASAP with our sights set on an admission to NASDAQ within the next 2/3 years, and I omit Avidamab and COVIDITY to stress the value attached to Immunabody and Moditope alone.
Well it sure makes for exciting times now that particular elephant in the room has been taken away, which is why afte deciding more than a few times to not invest more, do exactly the opposite with another £4k today.
So Bunsie, yes a great idea, one I am sure we will agree to adopt, and we wil just have to wait until the 9th of November to hear what news Scancell have to release before deciding what questions we should be asking. For me and my further investment I believe we will be getting news after the OO placing is concluded up until the 9th November the date of the AGM.
Good luck to all, whatever you decide, for me it wasn"t just a case of being able to afford more, but a case of could I afford not too. ATVB and GN, I think tomorrow we turn blue again.
Bunsie,
You may be thinking of Timbo? He doesn’t post much so you may want to get someone more “active”. He will probably have a number of probing questions of his own to put to the AGM.
ATB
Hi C7,
Just struggling a little today, think my hip mileage has been exceeded during lock-down. Ouch!
Going for a rest shortly!
ATB
Bunsie
Evening C7,
Yes a possible with Burble, but maybe someone else who may support a broader view outside of the science? Trying to keep this even for all PI's
Who used to do the update on previous AGM's and post it back to us all, just can't remember, he was very good back then IMO.
I am happy to run with the PI team's opinion though.
Just my thoughts on this, as a number of pointed questions to the BOD is far better than many of the same.
ATB
Bunsie
Very good idea Bunsie, the first name that springs to mind is Burble, if he wanted to do that, with no disrespect to many others.
Evening Ray,
Many thanks for the info, perhaps good to get a small list from all PI's and just one poses the questions?
I have seen this situation before and just countless lines of the same questions just clogs up the system.
We have time on our hands to do this effectively, not like test and trace I may add.
Who do we trust though to handle this on this BB, I have a few in mind, just regular guys/gals who stay relatively impartial.
We certainly don't want a Friday fight night situation.
I can't remember who used to do the whole AGM's report but thought it good anyway, maybe someone could refresh my memory.
Time for us all to pull together on this one.
ATB
Bunsie
snap crumbs
" A recorded presentation by the Company's management team outlining the Company's progress will be uploaded to the Company's website by 16:00 GMT on Monday, 9th November."
" Shareholders will be given the opportunity to email questions to the Board which must be received by 10:00 GMT on Friday, 13th November"
So we have time between these 2 date/times to watch the presentation and work out any questions not covered by the presentation.
Ahh I get it now.... So then we dial in to listen to the AGM boring bits and then whatever questions they have chosen to answer
So I suppose from that Monday update we can decide on what would be the most relevant and revealing questions we can put forwards...
Crumbs, the recorded presentation will be released ahead of the AGM and before the deadline for questions.
"A recorded presentation by the Company's management team outlining the Company's progress will be uploaded to the Company's website by 16:00 GMT on Monday, 9th November."
At least it will surely be the least expensive AGM ever :) ....
So it is going to be a pre recorded AGM? strange.... hmm maybe we do need to do a questions list and email it enmass?
From the RNS:
1. Questions
Shareholders will be given the opportunity to email questions to the Board which must be received by 10:00 GMT on Friday, 13th November. The email address for these questions is investor.enquiries@scancell.co.uk. Whilst the Company may not be in a position to answer every question it receives, it will address the most prominent within the confines of information already disclosed to the market through regulatory announcements.
2. Attending
· Shareholders will be able to dial into the formal AGM on Tuesday, 17th November when the previously submitted questions will be addressed by the Board. The phone number for the dial in will be available on the Company's website on the morning of the AGM.
("Scancell" or the "Company")
Notice of Annual General Meeting
Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, announces that the Company's Annual General Meeting ("AGM") will take place on Tuesday, 17th November 2020 at 14:00 GMT and the Notice of AGM has been posted to shareholders today. A copy of the Notice has been uploaded to Scancell's website: www.scancell.co.uk/documents-presentations
The Company continues to monitor the COVID-19 situation closely, including UK Government legislation and guidance, and will continue to do so in the lead up to the AGM. In line with the current UK Government advice, the Board of Directors of the Company (the "Directors" or the "Board") has taken the decision that shareholders, advisers and other guests will not be allowed to attend the AGM in person and anyone seeking to attend the AGM will not be permitted entry.
In light of these measures, the Board strongly encourages shareholders to vote by proxy in accordance with the instructions in the Notice of AGM.
In order to provide shareholders with the opportunity to ask questions at the AGM, the Company will set up the following:
· A recorded presentation by the Company's management team outlining the Company's progress will be uploaded to the Company's website by 16:00 GMT on Monday, 9th November.
· Shareholders will be given the opportunity to email questions to the Board which must be received by 10:00 GMT on Friday, 13th November. The email address for these questions is investor.enquiries@scancell.co.uk. Whilst the Company may not be in a position to answer every question it receives, it will address the most prominent within the confines of information already disclosed to the market through regulatory announcements.
· Shareholders will be able to dial into the formal AGM on Tuesday, 17th November when the previously submitted questions will be addressed by the Board. The phone number for the dial in will be available on the Company's website on the morning of the AGM.
Company's Annual General Meeting ("AGM") will take place on Tuesday, 17(th) November 2020 at 14:00 GMT